Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1038/nature12122

http://scihub22266oqcxt.onion/10.1038/nature12122
suck pdf from google scholar
C4512754!4512754 !23636326
unlimited free pdf from europmc23636326
    free
PDF from PMC    free
html from PMC    free

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=23636326 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi


Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\23636326 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117
pmid23636326
      Nature 2013 ; 497 (7448 ): 217-23
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • mTOR kinase structure, mechanism and regulation #MMPMID23636326
  • Yang H ; Rudge DG ; Koos JD ; Vaidialingam B ; Yang HJ ; Pavletich NP
  • Nature 2013[May]; 497 (7448 ): 217-23 PMID23636326 show ga
  • The mammalian target of rapamycin (mTOR), a phosphoinositide 3-kinase-related protein kinase, controls cell growth in response to nutrients and growth factors and is frequently deregulated in cancer. Here we report co-crystal structures of a complex of truncated mTOR and mammalian lethal with SEC13 protein 8 (mLST8) with an ATP transition state mimic and with ATP-site inhibitors. The structures reveal an intrinsically active kinase conformation, with catalytic residues and a catalytic mechanism remarkably similar to canonical protein kinases. The active site is highly recessed owing to the FKBP12-rapamycin-binding (FRB) domain and an inhibitory helix protruding from the catalytic cleft. mTOR-activating mutations map to the structural framework that holds these elements in place, indicating that the kinase is controlled by restricted access. In vitro biochemistry shows that the FRB domain acts as a gatekeeper, with its rapamycin-binding site interacting with substrates to grant them access to the restricted active site. Rapamycin-FKBP12 inhibits the kinase by directly blocking substrate recruitment and by further restricting active-site access. The structures also reveal active-site residues and conformational changes that underlie inhibitor potency and specificity.
  • |Adaptor Proteins, Signal Transducing/chemistry/metabolism [MESH]
  • |Adenosine Triphosphate/chemistry/metabolism [MESH]
  • |Catalytic Domain/drug effects [MESH]
  • |Crystallography, X-Ray [MESH]
  • |Furans/chemistry/pharmacology [MESH]
  • |Humans [MESH]
  • |Indoles/chemistry/metabolism/pharmacology [MESH]
  • |Magnesium/chemistry/metabolism [MESH]
  • |Models, Molecular [MESH]
  • |Naphthyridines/chemistry/metabolism/pharmacology [MESH]
  • |Protein Structure, Tertiary/drug effects [MESH]
  • |Purines/chemistry/metabolism/pharmacology [MESH]
  • |Pyridines/chemistry/pharmacology [MESH]
  • |Pyrimidines/chemistry/pharmacology [MESH]
  • |Ribosomal Protein S6 Kinases, 70-kDa/metabolism [MESH]
  • |Sirolimus/chemistry/metabolism/pharmacology [MESH]
  • |Structure-Activity Relationship [MESH]
  • |TOR Serine-Threonine Kinases/antagonists & inhibitors/*chemistry/*metabolism [MESH]
  • |Tacrolimus Binding Protein 1A/chemistry/metabolism/pharmacology [MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box